Latest News
These under-the-radar companies may offer greater long-term rewards.
We are looking for U.S.-listed equities that are attractive for trend-followers
Why Ardelyx Stock Soared Today
Ardelyx delivered a strong quarter thanks to solid demand for its first FDA-approved product. Here's what investors need to know.
Why Ardelyx Stock Popped Today
Ardelyx finally received the long-awaited FDA approval for its chronic kidney disease drug.
A Massachusetts-based biotech company found tremendous success on Wednesday after it was announced that the FDA approved the company’s Xphozah, the first and only phosphate absorption inhibitor, according to the release.This cased shares of Ardelyx Inc. (Nasdaq:ARDX) to get massively bid up on Wednesday, with shares reaching $4.12/share (+19.42%) at...
Why Shares of Ardelyx Were Down Wednesday
The company's hopes for approval of a drug to treat chronic kidney disease took a hit.
Morning Markets September E-Mini S&P 500 futures (ESU2 3) this morning are up +0.27%, and Sep Nasdaq 100 E-Mini futures (NQU2 3) are up +0.12%. Stock indexes this morning are moderately higher on mild short covering ahead of Fed Chair Powell’s speech later this morning at Jackson Hole, Wyoming. Slightly...
September S&P 500 futures (ESU23) are trending up +0.26% this morning as market participants awaited Federal Reserve Chair Jerome Powell’s speech for further clues on the outlook for interest rates.
Ardelyx, Inc. Reports Employment Inducement Grants
/PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative...
The Chart of the Day belongs to the biotechnology company Ardelyx (ARDX) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the Flipchart feature...
FDA Grants Appeal for Ardelyx's XPHOZAH® (tenapanor)
/PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative...
Ardelyx, Inc. Reports Employment Inducement Grants
/PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative...
March S&P 500 futures (ESH23) are trending up +0.39% this morning after three major U.S. benchmark indices slid for a third successive session and suffered a second consecutive week of losses on Friday as hawkish tone from the Federal Reserve and soft economic data bolstered investors' fears about a recession in the new year.
Ardelyx Provides Update on FDA Appeal for XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
/PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative...
Ardelyx to Present at the 34th Annual Piper Sandler Healthcare Conference
/PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative...
Ardelyx is relatively new to the market and was doing well until a small drug approval issue last year. Strong earnings and smart partnerships could save them
2 Biotech Stocks That Can Rocket Higher in 2023, According to Wall Street
Recent analyst upgrades suggest these stocks can triple your money or better.
Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
/PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative...
National Kidney Foundation and Ardelyx, Inc. Survey Finds Dialysis Patients Struggle to Maintain Serum Phosphorus Levels
/PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX) in partnership with the National Kidney Foundation (NKF), today announced results from a survey of patients with...
Ardelyx, Inc. Reports Employment Inducement Grants
/PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative...
Ardelyx Reports Second Quarter 2022 Financial Results and Recent Business Highlights
/PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative...
Ardelyx, Inc. Reports Employment Inducement Grants
/PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative...
Ardelyx Announces $20 Million Financing Agreement with HealthCare Royalty Partners
/PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative...
ARDELYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ardelyx, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Ardelyx, Inc. (NASDAQ: ARDX) on behalf of long-term stockholders following a class action complaint that was filed...
Ardelyx Announces Four Tenapanor Presentations at ASN's Kidney Week 2021
/PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative...